Drug intelligence / Profile preview

Veillonella atypica FB0054

Development stage: Unknown
Lead developer: FitBiomics
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

Veillonella atypica FB0054 is a next-generation probiotic strain developed by FitBiomics. It is a member of the Veillonella genus, which is known to colonize the human gut and metabolize lactate (lactic acid) produced during exercise into propionate, a short-chain fatty acid that serves as an energy source. By reducing systemic lactate levels and increasing propionate, the probiotic is intended to improve physical endurance, increase energy levels, and decrease fatigue. The strain was originally identified in the microbiomes of elite athletes and has been evaluated in clinical trials for its performance-enhancing and anti-fatigue properties.

Other names: Veillonella atypica FB0054V. atypica FB0054

Beyond the preview

Go deeper on Veillonella atypica FB0054.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Veillonella atypica FB0054.

Explore the full profile